Table IIIa:
Hazard Ratio for Risk of All-Cause Death, by Age Group, in patients with cutaneous melanoma in California, 2004 – 2015 (with follow-up through 2017)
| AYA (15 – 39) | Older Adults (40 – 64) | |||
|---|---|---|---|---|
| HR (95% CI) | aHR1 (95% CI) | HR (95% CI) | aHR1 (95% CI) | |
|
|
||||
| Sex | ||||
| Female | 1.00 | 1.00 | 1.00 | 1.00 |
| Male | 2.45 (2.08–2.88) | 1.43 (1.21–1.70) | 1.89 (1.79–2.00) | 1.39 (1.31–1.47) |
| Race/Ethnicity | ||||
| NHW | 1.00 | 1.00 | 1.00 | 1.00 |
| Hispanic | 1.82 (1.46–2.27) | 1.06 (0.84–1.35) | 1.57 (1.43–1.74) | 0.91 (0.82–1.01) |
| Black | 0.58 (0.08–4.09) | 0.09 (0.01–0.64) | 3.23 (2.34–4.46) | 1.32 (0.95–1.83) |
| Asian/P.I. | 2.08 (1.22–3.54) | 1.55 (0.90–2.66) | 2.37 (1.92–2.92) | 1.11 (0.90–1.38) |
| Other | 0.11 (0.05–0.21) | 0.25 (0.13–0.53) | 0.11 (0.09–0.14) | 0.18 (0.14–0.23) |
| Socioeconomic Status | ||||
| Highest | 1.00 | 1.00 | 1.00 | 1.00 |
| High-Middle | 1.15 (0.90–1.46) | 1.01 (0.79–1.30) | 1.45 (1.35–1.56) | 1.29 (1.19–1.38) |
| Middle | 1.86 (1.46–2.36) | 1.50 (1.17–1.91) | 1.79 (1.66–1.93) | 1.39 (1.28–1.50) |
| Low-Middle | 2.57 (2.00–3.31) | 1.25 (0.95–1.64) | 2.52 (2.33–2.73) | 1.58 (1.46–1.72) |
| Lowest | 3.67 (2.80–4.82) | 1.45 (1.08–1.96) | 3.46 (3.16–3.80) | 1.85 (1.68–2.04) |
| Insurance Status | ||||
| Private | 1.00 | 1.00 | 1.00 | 1.00 |
| Medicaid | 8.31 (6.78–10.17) | 2.47 (1.96–3.12) | 6.44 (5.92–7.00) | 2.07 (1.89–2.27) |
| Medicare | 6.97 (4.74–10.25) | 2.99 (2.01–4.45) | 3.44 (3.15–3.76) | 2.15 (1.96–2.35) |
| Military | 2.49 (1.60–3.86) | 2.03 (1.30–3.18) | 2.09 (1.82–2.40) | 1.57 (1.37–1.81) |
| Uninsured | 2.14 (1.43–3.18) | 1.60 (1.07–2.41) | 2.62 (2.30–2.99) | 1.74 (1.52–1.99) |
| Other/Unknown | 0.53 (0.40–0.71) | 0.75 (0.56–1.01) | 0.77 (0.72–0.83) | 1.18 (1.09–1.28) |
| Clinical Stage | ||||
| In-Situ/Stage I | 1.00 | 1.00 | 1.00 | 1.00 |
| Stage II | 11.90 (9.09–15.58) | 2.08 (1.36–3.18) | 5.67 (5.23–6.15) | 1.53 (1.33–1.77) |
| Stage III | 17.22 (13.61–21.79) | 3.31 (2.27–4.83) | 10.94 (10.14–11.80) | 3.18 (2.80–3.62) |
| Stage IV | 152.08 (121.20–190.82) | 20.39 (13.30–31.20) | 55.12 (51.32–59.20) | 10.79 (9.33–12.48) |
| Unknown | 6.52 (4.87–8.73) | 2.08 (1.32–3.27) | 3.90 (3.55–4.28) | 1.50 (1.29–1.74) |
| Location | ||||
| Limbs | 1.00 | 1.00 | 1.00 | 1.00 |
| Head/Neck | 1.53 (1.19–1.97) | .95 (0.73–1.24) | 1.48 (1.38–1.59) | 1.42 (1.32–1.53) |
| Trunk | 1.20 (0.98–1.47) | 1.12 (0.91–1.38) | 1.33 (1.25–1.42) | 1.19 (1.11–1.27) |
| Other | 25.48 (20.42–31.78) | 2.32 (1.64–3.29) | 18.11 (16.73–19.60) | 1.92 (1.68–2.18) |
| Histology 2 | ||||
| SSM | 1.00 | 1.00 | 1.00 | 1.00 |
| NM | 8.92 (6.49–12.27) | 0.86 (0.60–1.23) | 6.12 (5.52–6.78) | 1.30 (1.16–1.45) |
| ALM | 4.05 (1.96–8.39) | 1.13 (0.53–2.41) | 3.28 (2.59–4.16) | 1.26 (0.99–1.61) |
| LMM | 1.22 (0.53–2.81) | 1.99 (0.86–4.61) | 0.86 (0.75–0.98) | 1.06 (0.92–1.22) |
| NOS/Other | 2.25 (1.77–2.87) | 1.08 (0.83–1.40) | 1.57 (1.45–1.69) | 1.08 (1.00–1.17) |
| Year oi Diagnosis | ||||
| 2004 – 2006 | 1.00 | 1.00 | 1.00 | 1.00 |
| 2007 – 2009 | 0.98 (0.80–1.19) | 0.99 (0.80–1.21) | 0.92 (0.87–0.98) | 0.98 (0.92–1.04) |
| 2010 – 2012 | 1.09 (0.88–1.35) | 1.04 (0.83–1.29) | 0.80 (0.74–0.86) | 0.81 (0.75–0.87) |
| 2013 – 2015 | 0.59 (0.43–0.81) | 0.57 (0.42–0.79) | 0.61 (0.56–0.67) | 0.62 (0.57–0.69) |
| Tumor Thickness | ||||
| In-Situ/<1.00mm | 1.00 | 1.00 | 1.00 | 1.00 |
| 1.00-<2.00mm | 6.22 (4.70–8.23) | 3.27 (2.35–4.54) | 3.12 (2.86–3.39) | 1.87 (1.69–2.07) |
| 2.00-<4.00mm | 14.91 (11.27–19.71) | 3.68 (2.37–5.71) | 6.62 (6.07–7.23) | 2.08 (1.80–2.40) |
| ≥4.00mm | 35.97 (27.69–46.73) | 5.58 (3.56–8.73) | 13.73 (12.68–14.87) | 2.87 (2.49–3.31) |
| Unknown | 28.61 (22.71–36.03) | 3.51 (2.17–5.66) | 12.92 (12.09–13.81) | 2.40 (2.06–2.81) |
| Ulceration | ||||
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 9.96 (8.20–12.10) | 1.73 (1.34–2.23) | 6.70 (6.28–7.15) | 1.70 (1.56–1.85) |
| Unknown | 6.16 (5.05–7.51) | 1.15 (0.89–1.49) | 4.72 (4.42–5.04) | 1.30 (1.19–1.42) |
1
Fully adjusted models represent mutual adjustment for all the variables shown in the table
2
Histology definitions: SSM=Superficial Spreading Melanoma, NM=Nodular Melanoma, ALM=Acral Lentiginous Melanoma. LMM=Lentigo Maligna Melanoma, NOS/Other=Malignant Melanoma, NOS, and other rare subtypes.